205 related articles for article (PubMed ID: 33959786)
1. Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia.
Youssef YH; Makkeyah SM; Soliman AF; Meky NH
Cancer Chemother Pharmacol; 2021 Aug; 88(2):313-321. PubMed ID: 33959786
[TBL] [Abstract][Full Text] [Related]
2. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.
Rousseau J; Gagné V; Labuda M; Beaubois C; Sinnett D; Laverdière C; Moghrabi A; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Krajinovic M
Blood; 2011 Nov; 118(22):5883-90. PubMed ID: 21972289
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.
Ben Tanfous M; Sharif-Askari B; Ceppi F; Laaribi H; Gagné V; Rousseau J; Labuda M; Silverman LB; Sallan SE; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
Clin Cancer Res; 2015 Jan; 21(2):329-34. PubMed ID: 24907114
[TBL] [Abstract][Full Text] [Related]
4. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines.
Su N; Pan YX; Zhou M; Harvey RC; Hunger SP; Kilberg MS
Pediatr Blood Cancer; 2008 Feb; 50(2):274-9. PubMed ID: 17514734
[TBL] [Abstract][Full Text] [Related]
5. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
[TBL] [Abstract][Full Text] [Related]
6. Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
Abaji R; Gagné V; Xu CJ; Spinella JF; Ceppi F; Laverdière C; Leclerc JM; Sallan SE; Neuberg D; Kutok JL; Silverman LB; Sinnett D; Krajinovic M
Oncotarget; 2017 Jul; 8(27):43752-43767. PubMed ID: 28574850
[TBL] [Abstract][Full Text] [Related]
7. Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment.
Pastorczak A; Fendler W; Zalewska-Szewczyk B; Górniak P; Lejman M; Trelińska J; Walenciak J; Kowalczyk J; Szczepanski T; Mlynarski W;
Leuk Res; 2014 Feb; 38(2):180-3. PubMed ID: 24268318
[TBL] [Abstract][Full Text] [Related]
8. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
Tantawy AA; El-Bostany EA; Adly AA; Abou El Asrar M; El-Ghouroury EA; Abdulghaffar EE
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):28-34. PubMed ID: 19923983
[TBL] [Abstract][Full Text] [Related]
9. Trypsin-encoding
Wolthers BO; Frandsen TL; Patel CJ; Abaji R; Attarbaschi A; Barzilai S; Colombini A; Escherich G; Grosjean M; Krajinovic M; Larsen E; Liang DC; Möricke A; Rasmussen KK; Samarasinghe S; Silverman LB; van der Sluis IM; Stanulla M; Tulstrup M; Yadav R; Yang W; Zapotocka E; Gupta R; Schmiegelow K;
Haematologica; 2019 Mar; 104(3):556-563. PubMed ID: 30467200
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP1A1, GSTP1 and XRCC1 genes polymorphisms on toxicity and response to chemotherapy in childhood acute lymphoblastic leukemia.
Abo-Bakr A; Mossallam G; El Azhary N; Hafez H; Badawy R
J Egypt Natl Canc Inst; 2017 Sep; 29(3):127-133. PubMed ID: 28844589
[TBL] [Abstract][Full Text] [Related]
11. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
12. Correlations of IL-6 and IL-10 gene polymorphisms with childhood acute lymphoblastic leukemia.
Liu RT; Wang XX; Sun JR; Gao N; Yu WZ
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8048-8056. PubMed ID: 32767331
[TBL] [Abstract][Full Text] [Related]
13. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R
Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219
[TBL] [Abstract][Full Text] [Related]
14. Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia.
Dunn KA; Connors J; Bielawski JP; Nearing JT; Langille MGI; Van Limbergen J; Fernandez CV; MacDonald T; Kulkarni K
Leuk Lymphoma; 2021 Apr; 62(4):927-936. PubMed ID: 33258724
[TBL] [Abstract][Full Text] [Related]
15. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
16. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Gupta S; Wang C; Raetz EA; Schore R; Salzer WL; Larsen EC; Maloney KW; Mattano LA; Carroll WL; Winick NJ; Hunger SP; Loh ML; Devidas M
J Clin Oncol; 2020 Jun; 38(17):1897-1905. PubMed ID: 32275469
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia.
Rajić V; Debeljak M; Goričar K; Jazbec J
Leuk Lymphoma; 2015; 56(11):3103-8. PubMed ID: 25697915
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.
Iwamoto S; Mihara K; Downing JR; Pui CH; Campana D
J Clin Invest; 2007 Apr; 117(4):1049-57. PubMed ID: 17380207
[TBL] [Abstract][Full Text] [Related]
19. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
[TBL] [Abstract][Full Text] [Related]
20. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
